T ype 2 diabetes mellitus (T2DM) is characterized by the progressive loss of pancreatic β-cell function and insulin resistance, leading to increased risk of cardiovascular disease and microvascular disorders such as retinopathy and nephropathy.1,2 An increase in the understanding of the role of intestinal incretin hormones has provided additional therapeutic options in the treatment of T2DM.3 Several recent articles provide a review of the efficacy profile of dipeptidyl peptidase-4 (DPP-4) inhibitors based on emerging results from randomized clinical trials. 1,[4][5][6] Recently, sitagliptin (SITA) and saxagliptin (SAXA) were approved for use by the US Food and Drug Administration (FDA), and vildagliptin (VILD) has been approved for use by the European Medicines Agency (EMEA). Data to support the registration of alogliptin (ALOG) were submitted to the FDA in 2008. In general, these selective DPP-4 inhibitors have similar characteristics with respect to pharmacokinetics Dipeptidyl peptidase-4 (DPP-4) inhibition is a wellcharacterized treatment for type 2 diabetes mellitus (T2DM). The objective of this model-based meta-analysis was to describe the time course of HbA1c response after dosing with alogliptin (ALOG), saxagliptin (SAXA), sitagliptin (SITA), or vildagliptin (VILD). Publicly available data involving late-stage or marketed DPP-4 inhibitors were leveraged for the analysis. Nonlinear mixed-effects modeling was performed to describe the relationship between DPP-4 inhibition and mean response over time. Plots of the relationship between metrics of DPP-4 inhibition (ie
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.